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Objective: Thyroid hormones can lower levels of atherogenic lipoproteins, and selenium is important in thyroid
hormone homeostasis. We aimed to investigate the effects of a healthy diet associated with the Brazil nut
(Bertholletia excelsa) in dyslipidemic and hypertensive patients.
Methods: This study was a randomized, placebo-controlled, double-blind trial. Seventy-seven dyslipidemic and
hypertensive patients already receiving lipid-lowering drugs received either a dietary treatment associated with
partially defatted Brazil nut flour (13 g/day providing 227,5 μg of selenium/day),or with dyed cassava flour as a
placebo. All patients received a personalized dietary guideline with nutritional recommendations for dyslipidemia
and hypertension and were followed for 90 days.
Results: The Brazil nut group showed reductions in total cholesterol (−20.5 ± 61.2 mg/dL, P = 0.02), non HDL-cholesterol
(−19.5 ± 61.2 mg/dL, P = 0.02) and Apo A-1 (−10.2 ± 26.7 mg/dL, P = 0.03) without significant alterations in the Apo
B/Apo A-1 ratio. The placebo group showed a reduction in FT3 levels (−0.1 ± 0.4, P = 0.03) and increased Lp(a)
levels (5.9 ± 18.0 mg/dL, P = 0.02). There were no statistical differences in blood pressure and serum lipids between
Brazil nut and placebo group.
Conclusions: Supplementation with Brazil nuts seems to favor the maintenance of FT3 levels and contributes to
lipemia reduction in hypercholesterolemic and euthyroid patients.
Trial registration: ClinicalTrials.gov Identifier NCT01990391
Keywords: Brazil nut, Selenium, Serum lipids, Thyroid hormones, DyslipidemiaIntroduction
Atherosclerotic cardiovascular disease is has a high
worldwide prevalence and mortality [1]. Hyperlipidemia
increases the incidence and risk of this disease, as con-
firmed by several large-population studies [1, 2].* Correspondence: glorimar@nutricao.ufrj.br
1Post Graduate Program, Federal Universityof Rio de Janeiro, Professor
Rodolpho Paulo Rocco St, 225 Rio de Janeiro, Brazil
4Nutrition and Dietetic Department, Josué de Castro Institute of Nutrition,
Federal Universityof Rio de Janeiro, 373, 2nd floor, block J, Carlos Chagas
FilhoAv, Ilha do Governador, 21941-902 Rio de Janeiro, Brazil
Full list of author information is available at the end of the article
© 2015 Carvalho et al. This is an Open Access
(http://creativecommons.org/licenses/by/4.0),
provided the original work is properly credited
creativecommons.org/publicdomain/zero/1.0/It has been described that thyroid hormones and thyr-
omimetic drugs has LDL cholesterol (C) lowering effec
[3−7] and also reduce levels of other atherogenic lipo-
proteins such as triglycerides [5, 7], apolipoprotein B
(apo B) [6] and lipoprotein (a) (Lp(a)) [5−7], although
they also decrease levels of non-atherogenic lipoproteins,
such as apolipoprotein A-1 (apo A-1) [3]. These effects
may be caused by stimulation of LDL receptors, which
increases hepatic clearance and cholesterol elimination,
and presumably promotes reverse cholesterol transport,
even in individuals without subclinical hypothyroidism
[6, 8, 9].article distributed under the terms of the Creative Commons Attribution License
which permits unrestricted use, distribution, and reproduction in any medium,
. The Creative Commons Public Domain Dedication waiver (http://
) applies to the data made available in this article, unless otherwise stated.
Carvalho et al. Nutrition Journal  (2015) 14:59 Page 2 of 9Selenium is an essential micronutrient for the metabolism
of thyroid hormones, playing a major role in thyroxine con-
version to the more active metabolic form triiodothyronine
because the activity of some deiodinases is dependent on
selenium [10, 11]. The thyroid gland contains the highest
amount of selenium [10], and selenoprotein glutathione
peroxidase can protect the thyroid gland from the oxidative
damage produced during thyroid hormone synthesis [12].
Selenium also plays an important antioxidant role in cardio-
vascular disease and studies have shown that serum and
urinary levels of selenium are lower in patients who suffered
acute myocardial infarcts or ischemic cardiomyopathy [13].
The Brazil nut (Bertholletia excelsa, family Lecythida-
ceae) originates from the Amazon region and is the richest
known food source of selenium [14]. Most selenium con-
tent in this nut is present in protein fractions;therefore,
the cake protein has the highest amount of selenium pre-
sented as selenomethionine and selenocysteine [15]. The
high concentration of selenium in the Brazil nut may im-
prove serum lipoprotein, due to its stimulation of the
metabolically active form of thyroid hormones.
The present study investigated the effects of a healthy
diet associated with defatted Brazil nut flour on thyroid




The Ethics Committee for Clinical Research of the Na-
tional Cardiology Institute approved this study (protocol
number 316/2011) in Rio de Janeiro, Brazil. This study
was also registered at ClinicalTrials.gov (NCT01990391).
All patients were informed about the procedures and
gave their written informed consent.
Study patients
Eighty-nine dyslipidemic and hypertensive patients (49
men and 40 women) were recruitedat the National Insti-
tute of Cardiology at the Dyslipidemia and Atherosclerosis
Outpatient Clinic. Eligible patients were males and fe-
males aged 40 to 80 years old, with referred diagnoses of
dyslipidemia and hypertension who were taking medica-
tion for both conditions for at least 3 months before being
included in the study, and were diagnosed with euthyroid-
ism. Euthyrodism was defined as thyroid stimulating hor-
mone (TSH) (reference range, 0.45 – 4.50 μUI/mL) and
free thyroxine (FT4) (reference range, 0.70 – 1.48 ng/dL)
within the normal reference range [16].
Patients with history of thyroid disease, thyroid medica-
tion use, chronic renal failure with glomerular filtration rate
< 60 mL/min/1.73 m2 [17] were excluded. As well as those
currently or previously having ingested supplements con-
taining > 20 μg Se/day, or presenting excessive consumption
of Brazil nuts in the past year, having plasma selenium levelsabove 125 μg/L [18], being current smokers [19], and hav-
ing been in a rigorous exercise/weight-reduction program
within the 3 months before entering the study.
Experimental design
This study was a 90-day randomized, placebo-controlled,
double-blind clinical trial. Eligible patients were randomly
assigned to one of two groups: diet + partially defatted
Brazil nut flour (n = 35) or diet + placebo (artificially fla-
vored dyed cassava flour) (n = 42).
Patients were randomized using the method of com-
puter generated random list restricted in blocking of 10
patients and sequentially numbered labels were inserted
in sealed containers with Brazil nut or placebo. The re-
searcher that generated the random allocation sequence
was not the same that enrolled participants and assigned
participants to interventions.
Patients were assessed before and during the 90-day trial,
with monthly blood test to measure thyroid hormones,
lipid profile, and plasma selenium levels. In addition, food
intake was analyzed through patients’ dietary anamnesis
whereas anthropometric data were evaluated through mea-
sures of waist circumference (WC) and body weight and
height, for calculation of body mass index (BMI). At each
visit, patients were given a sealed opaque flask containing
either 450 g of Brazil nut flour or placebo, and standard
measuring spoons. Plasma selenium levels were used as
markers of compliance to Brazil nut consumption.
Self-reported questionnaires were used to determine
physical activity [20], dietary habits, and medications.
Physical exercise was taken into account when patients
exercised at least once a week, and was reported as Meta-
bolic Equivalent of Task (MET), expressed in kcal/day
[21]. Patients were asked to maintain their normal amount
of physical activity and dose of lipid-lowering medication.
This was verified by analyzing questionnaires filled out by
patients and by examining the medical record containing
prescription information of each patient visit.
Nutritional intervention
Patients received either 13 g/day of partially defatted
Brazil nut flour providing 64.4 kcal, 0.17 g carbohydrate,
3.4 g protein, 5.56 g total fat, 2.58 g dietary fiber and
227.5 μg of selenium/day (Ouro Verde Amazônia® –
Mato Grosso, Brazil) or 11 g/day of artificially flavored
dyed cassava flour (Mane of Brazil Industry and Com-
merce Ltda – Rio de Janeiro, Brazil). The nutritional com-
position 11 g of placebo is: 36.5 kcal, 8.92 g carbohydrate,
0.12 g protein, 0.03 g total fat, 0.65 g dietary fiber [22] and
0.07 μg selenium [23]. The volume of Brazil nut and pla-
cebo was different because of the total volume of the
opaque flask used to store the supplements. Since placebo
was less dense, it requires a higher volume and more flasks,
so it could difficult the double blinding of the study.
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this study rather than the Brazil nut kernel because the
granulated Brazil nut has a higher Se content than the
Brazil nut kernel (227,5 μg vs. 249,21 μg [22, 23], re-
spectively) and they have similar centesimal composi-
tions except for less total fat and fewer calories. In
addition, granulated Brazil nut allowed for blinding the
study and is already commercialized.
The amount of selenium present in the Brazil nut flour
was measured by flame atomic absorption spectrometry.
The energy value of Brazil nut was 59 kcal/day while the
placebo group was 46.8 kcal/day.
The dietary plan was prescribed in accordance to the
volunteers’ dietary habits and nutritional recommenda-
tions according to guidelines for dyslipidemia and hyper-
tension [24, 25]. Participants also received a weekly
menu and healthy recipes. Dietary compliance was veri-
fied monthly at the check-up via 24 h diet reminders
that were analyzed with the Food Processor software,
version 12 (EshaResearch, Salem, USA, 1984).
Blood collection and biochemical evaluation
Blood samples were collected following 12 h of over-
night fasting and analyzed at the Clinical Analyses
Laboratory of National Cardiology Institute (Rio de
Janeiro, Brazil) using an automated method (ARCHI-
TECT ci8200, Abbott ARCHITECT®, Abbott Park, IL,
USA) and commercial kits (Abbott ARCHITECT
c8000®, Abbott Park, IL, USA).
Serum TSH and thyroid hormones free triiodothyrodine
(FT3) and free thyroxine (FT4) were measured by
immunochemiluminescence of microparticle [26, 27] with
analytical sensitivity of 1 pg/mL for FT3, 0.4 ng/dL for
FT4, and 0.0025 μUI/mL for TSH.
Serum concentrations of triglycerides, total cholesterol,
and HDL-c were assayed by enzymatic-colorimetric
methods: glycerol phosphate oxidase/peroxidase [28],
cholesterol oxidase/peroxidase [29], and direct deter-
gent [30], respectively. Non-HDL cholesterol was cal-
culated as follows: total cholesterol – HDL-c [31].
LDL-c values were obtained according to the Friede-
wald formula [32]. Serum levels of Apo A-1 and Apo
B were measured with immunoturbidimetry [33]. The
Apo B / Apo A-1 ratio was obtained using the con-
ventional values. To determine plasma Lp(a) levels,
collecting was carried out with tubes containing eth-
ylenediaminetetraacetic acid (EDTA), and analyses
were conducted by particle-enhanced turbidimetric
immunoassay [34].
Plasma selenium was analyzed in samples collected in NH
Trace Element tubes with sodium heparin (VACUETTE®)
and were maintained at −70 °C until they were analyzed
with atomic absorption spectrometry using an inductively
coupled plasma mass spectrometer (NexION™ 300 ICP-MS,PerkinElmer, Massachusetts, USA) [35]. This analysis was
conducted at the LABSPECTRO Laboratory of the Pontif-
ical Catholic University (Rio de Janeiro, Brazil).
Statistical analyses
The estimated sample size was based on detection of a
significant mean increase in T3 levels of 0.07 ±
0.2 nmol/l, with selenium supplementation at a dosage
of 200 μg/d during three months, as one of the objec-
tives of this study. It was used a two-sided type I error
of less than 5 %. Thus, 70 patients was required for a
statistical power of 80 %.
All statistical analyses were conducted using the Statis-
tical Package Social Sciences (SPSS) software, version 16.
Results were reported as mean ± SD. Data normality was
tested by Shapiro-Wilk W test and the chi-square test to
assess the differences in the qualitative variables between
groups. To evaluate the effect of Brazil nut consumption
on the investigated variables, we used the Mann-Whitney
U test to analyze between-group differences and a Wil-
coxon Signed Ranks test to assess changes in each group
for non-normal data. Finally, for normal data, the
Independent-Simple Student t-Test was used to compare
means between groupsand the Paired-Simple Student
t-Test was used to assess differences in each group
throughout the study. Significant differences were as-
sumed at P < 0.05.
Results
Of the 89 patients randomized, 12 did not complete the
study (Fig. 1). No adverse effects were reported by any of
the participants. One patient discontinued consuming
Brazil nut due to pleural effusion, but this condition was
unrelated to the supplementation, as this patient had a
history of coronary artery disease. Seventy-seven patients
completed the study; 35 in the diet + Brazil nut group and
42 in the diet + placebo group. The patients who did not
complete the study had the same investigated characteris-
tics as those who completed it (Table 1).
At baseline, the groups did not differ in terms of age,
sex, BMI, diabetes mellitus diagnosis, plasma selenium
levels, physical activity, and medications (Table 2). Like-
wise, there was no statistically significant difference be-
tween the groups in terms of daily dietary components
(Table 3) and the variables studied (Table 4) at baseline.
Patients kept their usual levels of physical activity dur-
ing the study, thus maintaining their caloric expenditure.
There were no significant changes in BMI (Brazil nut
group: Δ T90 – T0 = −0.2 ± 0.7 kg/m
2; placebo group: Δ
T90 – T0 = −0.1 ± 0.9 kg/m
2) and WC (Brazil nut group:Δ
T90 – T0 = −0.6 ± 2.5 cm; placebo group: Δ T90 – T0 = −
0.5 ± 3.3 cm) within and between groups.
Plasma selenium concentrations increased significantly
in the Brazil nut group at all time-points (Δ T90 – T0 =
Fig. 1 Flowchart of participants in the randomized clinical trial
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other hand, those concentrations decreased significantly at
T30 and T60 (Δ T60 – T0 = − 17.2 ± 23.4 μg/L, P < 0.001).
Selenium levels differed significantly between groups
at all time-points, except at baseline (T90: Brazil nut =
169.5 ± 46.5 μg/L versus placebo = 92.7 ± 16.8 μg/L,
P < 0.001) (Fig. 2).
Due to the nutritional recommendations, energy intake
decreased significantly in both the Brazil nut (P = 0.03)
and placebo (P < 0.001) groups, while selenium intake in-
creased significantly in the Brazil nut group (P < 0.001)
(Table 3).
Thyroid hormone profiles are presented in Table 4.
There were no statistical differences in TSH and FT4
levels within and between groups, while FT3 decreased
significantly only in the placebo group (P = 0.03) at T90,
without alterations between groups.Serum lipoprotein levels are presented in Table 4.
There were no significant differences within or between
groups in LDL-c, HDL-c, triglycerides, Apo B and
the Apo B / Apo A-1 ratio during the study. After
90 days, total cholesterol (P = 0.02), non-HDL choles-
terol (P = 0.02) and Apo A-1 (P = 0.03) decreased sig-
nificantly only in the Brazil nut group, however there
was no difference between groups. The placebo group
presented an increase in Lp(a) levels (P = 0.02). Figure 3
presents the changes in total cholesterol between
groups during the study.
Discussion
In this study, we analyzed the effects of a personalized
balanced diet associated with defatted Brazil nut flour
on the lipid levels and thyroid hormones of dyslipidemic
and hypertensive patients.






Age - years 60.05 ± 10.27 61.50 ± 9.47 NS
Male – n (%) 43 (55.8 %) 6 (50.0 %) NS
Body mass index – kg/m2 29.54 ± 5.60 28.51 ± 3.38 NS
Plasma selenium - μg/L 87.57 ± 16.29 85.83 ± 18.67 NS
SBP (mmHg) 142.26 ± 28.40 136.08 ± 18.82 NS
DBP (mmHg) 82.19 ± 14.15 82.83 ± 9.47 NS
FT3 (pg/mL) 2.91 ± 0.41 2.93 ± 0.67 NS
FT4 (ng/dL) 1.20 ± 0.18 1.21 ± 0.15 NS
Total cholesterol (mg/dL) 217.88 ± 89.96 203.83 ± 56.26 NS
LDL-cholesterol (mg/dL) 130.10 ± 58.42 131.33 ± 49.22 NS
HDL-cholesterol (mg/dL) 38.83 ± 12.94 38.17 ± 9.81 NS
Triglycerides (mg/dL) 230.88 ± 224.09 194.58 ± 109.74 NS
Mean ± SD or n (%). SBP systolic blood pressure; DBP diastolic blood pressure;
FT3 free triiodothyronine; FT4 free thyroxine; LDL low density lipoprotein; HDL
high density lipoprotein
For quantitative variables, we used a Student’s t test for independent samples
(selenium and age) or a Mann–Whitney U test for variables with normal and
non-normal distributions, respectively. For categorical variables, we used a
Chi-squared test. There was no significant difference between groups at baseline
Table 2 Baseline characteristics of the study patients
Characteristics Brazil nut (n = 35) Placebo (n = 42)
Age – years 59.6 ± 10.8 60.4 ± 9.9
Elderly – n (%)* 19 (54.3 %) 22 (52.4 %)
Male – n (%) 20 (57.1 %) 23 (54.8 %)
Diabetes – n (%) 17 (48.6 %) 15 (35.7 %)
BMI– kg/m2 29.9 ± 6.5 29.3 ± 4.8
Overweight / obesity – n. (%) 27 (77.1 %) 35 (83.3 %)
Plasma selenium - μg/L 88.7 ± 15.3 86.6 ± 17.2
Physical activity – n (%)† 13 (37.1 %) 14 (33.3 %)
MET (kcal/day) 23.8 ± 46.1 27.1 ± 53.8
Drug therapy – n (%)
Lipid-lowering drugs
Statins 31 (88.6) 35 (83.3)
Ezetimibe 18 (51.4) 15 (35.7)
Fibrate 15 (42.8) 14 (33.3)
Antihypertensive drugs
Diuretics 25 (71.4) 26 (61.9)
ACE Inhibitors 16 (45.7) 22 (52.4)
Calcium channel blockers 14 (40.0) 15 (35.7)
Sympatholytic 31 (88.6) 35 (83.3)
Vasodilators 16 (45.7) 20 (47.6)
ARB 13 (37.1) 14 (33.3)
Mean ± SD or n (%). BMI Body mass index; MET metabolic equivalent; ACE
angiotensin-converting enzyme; ARB angiotensin II receptor blockers
* Individuals older than 60
† Expressed as the percentage of individuals who responded positively to
these questions (% Yes)
For quantitative variables, we used a Student’s t test for independent samples
(selenium and age) or a Mann–Whitney U test for variables with normal and
non-normal distributions, respectively. For categorical variables, we used a chi-
squared test. There was no significant difference between groups at baseline
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artificially containing high amounts of selenium improve
lipid profiles, with significant reductions in total choles-
terol and non-HDL cholesterol levels [36, 37], which is
supported by the present study. Moreover, Maranhão
et al. [37] showed a significant reduction in LDL-c levels.
Other authors who used selenium supplements in doses
greater than 290 μg/day did not observe significant reduc-
tion in atherogenic lipoproteins, even though they did ob-
serve increase in HDL-c levels [36, 38].
These beneficial effects in the lipid profile resulting
from Brazil nut consumption may be due to selenium’s
ability to maintain the metabolically active form of
thyroid hormones, as recent studies have shown that
using thyroid hormone analogues such as eprotirome
(KB2115) favors reduction in serum lipoproteins in eu-
thyroid patients [6, 39].
Decreases in the non-atherogenic lipoprotein Apo A-1
levels observed in the current study are in line with pre-
vious studies in which patients displayed lower Apo A-1
levels after receiving thyromimetic medications [6, 39]
and in hyperthyroidism [39]. On the other hand, we
found no changes in the Apo B / Apo A-1 ratio, indicat-
ing no deleterious effect on reverse cholesterol transport,
as a significant reduction of non-HDL cholesterol was
observed.
Lp(a), one of the most atherogenic lipoproteins, is
greatly determined (> than 90 %) by genetic factors and is
little influenced by diet and lifestyle. Most lipid-loweringmedications have no significant influence on Lp(a) [40]. It
is well-established that many hormones have a strong ef-
fect on Lp(a) metabolism, and the thyroid hormone T3
seems to provide a significant reduction in plasma Lp(a)
levels [5, 7]. Thus, the plasma Lp(a) level increases ob-
served in the placebo group could be explained by the
serum reduction of FT3 levels.
In the current study, a significant reduction in serum
FT3 levels was observed only in the placebo group.
These hormonal alterations could be explained by the ef-
fect of energy intake reduction, as previous studies have
shown that these alterations can be diet-induced [41,
42]. On the other hand, the Brazil nut group maintained
FT3 levels, which may be explained by the fact that sel-
enium favors increases in the more metabolically active
form of thyroid hormones [43–47].
The selenium status at baseline, in the sample popula-
tion of the present study, was below the normal range
Table 3 Dietary data for the two study groups
Dietary component (intake/day) Brazil nut (n = 35) Δ
T90 – T0








Energy intake (kcal) - 232.3 ± 153.7 - 390.1 ± 534.0 0.030* <0.001* NS
Lipids (%) 0.2 ± 5.4 - 0.6 ± 7.4 NS NS NS
Saturated FA (%) - 0.4 ± 2.4 - 0.7 ± 3.3 NS NS NS
Monounsaturated FA (%) 0.3 ± 3.0 −0.6 ± 4.1 NS NS NS
Polyunsaturated FA (%) 0.2 ± 1.6 0.2 ± 1.3 NS NS NS
n-3 polyunsaturated FA (g) - 0.1 ± 0.3 −0.1 ± 0.4 NS NS NS
Carbohydrates (%) −2.4 ± 11.1 2.5 ± 12.3 NS NS NS
Proteins (%) 1.8 ± 9.2 1.0 ± 10.0 NS NS NS
Selenium (μg) 231.1 ± 35.3 −8.2 ± 44.0 <0.001* NS <0.001*
Mean ± SD. FA, fatty acids; NS, non-significant
* Significant differences were assumed at P < 0.05
a Statistical differences in Brazil nut group compared to baseline
b Statistical difference in placebo group compared to baseline
c Statistical differences between groups compared at T90
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glutathione peroxidase activity, established as 90 to
125 μg/l [18]. We suggest this occurs because of the in-
creased oxidative stress in dyslipidemia [48].
The reduction in plasma selenium concentrations in the
placebo group could be due to the nutritional recommen-
dations for individuals with dyslipidemia, as the main foodTable 4 Thyroid hormones, blood pressure and serum lipoproteins




FT3 (pg/mL) 0.1 ± 1.1 −0.1 ± 0
FT4 (ng/dL) 0.1 ± 0.6 −0.1 ± 0
TSH (μUI/mL) 0.2 ± 1.8 −0.2 ± 0
SBP (mmHg) 3.5 ± 18.0 −4.0 ± 3
DBP (mmHg) −1.5 ± 13.6 −5.0 ± 1
Total cholesterol (mg/dL) −20.5 ± 61.2 −7.4 ± 4
LDL-cholesterol (mg/dL) −6.4 ± 57.9 −6.5 ± 3
HDL-cholesterol (mg/dL) −1.0 ± 5.0 0.8 ± 7.1
Triglycerides (mg/dL) −49.6 ± 198.2 −0.05 ±
Non-HDL cholesterol (mg/dL) −19.5 ± 61.2 −8.2 ± 4
Apolipoprotein A-1 (mg/dL) −10.2 ± 26.7 −7.9 ± 2
Apolipoprotein B (mg/dL) −5.2 ± 25.9 −5.0 ± 2
ApoB/ApoA-1 ratio 0.02 ± 0.2 −0.06 ±
Lp(a) (mg/dl) −0.5 ± 23.7 5.9 ± 18.
Mean ± SD. FT3, free triiodothyronine; FT4, free thyroxine; TSH, thyroid stimulating h
apolipoprotein B; ApoA-1, apolipoprotein A-1; Lp(a), lipoprotein (a)
a Statistical differences in Brazil nut group compared to baseline
b Statistical difference in placebo group compared to baseline
c Statistical differences between group compared at T90
* Significant differences were assumed at P < 0.05
For normally distributed variables (FT3 and FT4), we used a Student’s t test for indep
within and between groups, respectively. For non-normally-distributed variables, we
differences within and between groups, respectivelysources of this trace element are offal, seafood, meats, and
cereals and grains [22]. The amount of selenium provided
in this study (≈200 μg) can be obtained by consuming 03
units of Brazil nut (102 Kcal) daily.
The present study showed that a small restriction in en-
ergy intake might not influence an individual’s lipid profile;
however, the consumption of Brazil nut in combinationat baseline and after the 90-day trial






.4 NS 0.030* NS
.1 NS NS NS
.9 NS NS 0.06
0.7 NS NS NS
5.2 NS 0.020* NS
4.5 0.020* NS NS
9.5 NS NS NS
NS NS NS
104.1 NS NS NS
4.5 0.020* NS NS
7.8 0.040* NS NS
3.4 NS NS NS
0.3 NS NS NS
0 NS 0.02* NS
ormone; SBP, systolic blood pressure; DBP, diastolic blood pressure, ApoB,
endent samples and a paired-samples t test to investigate the differences
used a Mann–Whitney U test and a Wilcoxon Signed Ranks test to assess the
Fig. 2 Plasma selenium levels in both groups over 90 days. Values are expressed as means and standard deviations with 95 % CI. n = 77. Values
were measured for both groups on days 0, 30, 60 and 90. Excluding baseline levels, values differed significantly within and between groups at
every time point
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profile. Nevertheless, there were not found statistical dif-
ferences in blood pressure and serum lipids between
groups of intervention, possibly because the nutritional
recommendation favored improves in these parameters in
both groups and due the complexity of these patients with
regard to disease duration, medication use and
heterogeneity.
Strengths and limitations
To our knowledge, this is the first randomized, double-
blind, placebo-controlled study to investigate the effects
of a personalized balanced diet associated with Brazil
nut consumption in dyslipidemic and hypertensive pa-
tients. The present study has limitations that may have
influenced the findings, including the group ofFig. 3 Serum total cholesterol levels in both groups over 90 days. Values a
Values were measured for both groups on days 0, 30, 60 and 90. Values difparticipants who did not complete the study. Consider-
ing the potential public health implications of our re-
sults, there is a need for more randomized studies with
larger patient groups, conducted in populations with a
wider range of plasma selenium concentrations, and no
medication use. In addition, in vitro studies are needed
to evaluate the fractional T3 that would be affected by
selenium supplements.
Conclusion
The reduction in energy intake associated with the con-
sumption of partially defatted Brazil nut flour (200 μg of
selenium/day) contributed to a reduction in serum total
cholesterol and non-HDL cholesterol levels in dyslipid-
emic and hypertensive patients undergoing drug treat-
ment, without altering thyroid hormone concentrations.re expressed as means and standard deviations with 95 % CI, n = 77.
fered significantly only for the Brazil nut group at the T90
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